☰

Theodore C. Goldstein, Ph.D. - Publications

Affiliations: 
Biomolecular Engineering and Bioinformatics University of California, Santa Cruz, Santa Cruz, CA, United States 
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Glicksberg BS, Burns S, Currie R, Griffin A, Wang ZJ, Haussler D, Goldstein T, Collisson E. Blockchain-Authenticated Sharing of Genomic and Clinical Outcomes Data of Patients With Cancer: A Prospective Cohort Study. Journal of Medical Internet Research. 22: e16810. PMID 32196460 DOI: 10.2196/16810  0.623
2019 Vaske OM, Bjork I, Salama SR, Beale H, Tayi Shah A, Sanders L, Pfeil J, Lam DL, Learned K, Durbin A, Kephart ET, Currie R, Newton Y, Swatloski T, McColl D, ... ... Goldstein TC, et al. Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. Jama Network Open. 2: e1913968. PMID 31651965 DOI: 10.1001/jamanetworkopen.2019.13968  0.553
2019 Yu K, Chen B, Aran D, Charalel J, Yau C, Wolf DM, van 't Veer LJ, Butte AJ, Goldstein T, Sirota M. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nature Communications. 10: 3574. PMID 31395879 DOI: 10.1038/S41467-019-11415-2  0.415
2019 Learned K, Durbin A, Currie R, Kephart ET, Beale HC, Sanders LM, Pfeil J, Goldstein TC, Salama SR, Haussler D, Vaske OM, Bjork IM. Barriers to accessing public cancer genomic data. Scientific Data. 6: 98. PMID 31222016 DOI: 10.1038/S41597-019-0096-4  0.596
2019 Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, et al. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 30804427 DOI: 10.1038/S41391-019-0134-5  0.658
2019 Datta D, Goldstein T, Butte A. Assessing real-world outcomes in precision oncology by linking clinical genomic testing to electronic medical records. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E18091  0.426
2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Goldstein TC, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 175: 889. PMID 30340047 DOI: 10.1016/J.Cell.2018.10.019  0.467
2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Goldstein TC, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. PMID 30033370 DOI: 10.1016/J.Cell.2018.06.039  0.493
2018 Kim W, Small EJ, Aggarwal RR, Den RB, Lehrer J, Zhang L, Youngren J, Goldstein TC, Alumkal JJ, Gleave M, Rettig M, Evans CP, Beer TM, Reiter RE, Huang J, et al. Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications. Journal of Clinical Oncology. 36: 197-197. DOI: 10.1200/Jco.2018.36.6_Suppl.197  0.504
2017 Newton Y, Novak AM, Swatloski T, McColl DC, Chopra S, Graim K, Weinstein AS, Baertsch R, Salama SR, Ellrott K, Chopra M, Goldstein TC, Haussler D, Morozova O, Stuart JM. TumorMap: Exploring the Molecular Similarities of Cancer Samples in an Interactive Portal. Cancer Research. 77: e111-e114. PMID 29092953 DOI: 10.1158/0008-5472.Can-17-0580  0.711
2017 Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, et al. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research. 77: e62-e66. PMID 29092942 DOI: 10.1158/0008-5472.Can-17-0582  0.381
2017 Morozova O, Salama SR, Bjork I, Goldstein TC, Mueller S, Sender LS, Sweet-Cordero A, Haussler D, Team CKCC. Comparative genomic analysis for pediatric cancer patients evaluated in a California Initiative to Advance Precision Medicine Demonstration Project. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps10578  0.617
2017 Learned K, Durbin A, Currie R, Beale H, Lam DL, Goldstein T, Salama SR, Haussler D, Morozova O, Bjork I. Abstract LB-338: A critical evaluation of genomic data sharing: Barriers to accessing pediatric cancer genomic datasets: a Treehouse Childhood Cancer Initiative experience Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-338  0.654
2017 Datta D, Goldstein T, Gu Z, Butte A. Abstract LB-006: Oncology model fidelity scores Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-006  0.411
2017 Morozova O, Newton Y, Shah AT, Beale H, Lam DL, Vivian J, Bjork I, Goldstein T, Stuart J, Salama S, Sweet-Cordero EA, Haussler D. Abstract 4890: A pan-cancer analysis framework for incorporating gene expression information into clinical interpretation of pediatric cancer genomic data Cancer Research. 77: 4890-4890. DOI: 10.1158/1538-7445.Am2017-4890  0.684
2017 Beale H, Lam DL, Vivian J, Newton Y, Shah AT, Bjork I, Goldstein T, Brooks AN, Stuart J, Salama S, Sweet-Cordero EA, Haussler D, Morozova O. Abstract 2466: Identifying confidently measured genes in single pediatric cancer patient samples using RNA sequencing Cancer Research. 77: 2466-2466. DOI: 10.1158/1538-7445.Am2017-2466  0.577
2016 Aggarwal RR, Youngren J, Sokolov A, Huang J, Thomas GV, True LD, Foye A, Alumkal JJ, Ryan CJ, Beer TM, Evans CP, Gleave M, Rettig M, Stuart JM, Lara P, ... Goldstein TC, et al. Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Journal of Clinical Oncology. 34: 5045-5045. DOI: 10.1200/Jco.2016.34.15_Suppl.5045  0.406
2016 Small EJ, Aggarwal RR, Huang J, Sokolov A, Zhang L, Alumkal JJ, Youngren J, Ryan CJ, Foye A, Reiter RE, Evans CP, Gleave M, Witte O, Stuart J, Goldstein TC, et al. Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT). Journal of Clinical Oncology. 34: 5019-5019. DOI: 10.1200/Jco.2016.34.15_Suppl.5019  0.488
2016 Morozova O, Newton Y, Cline M, Yip S, Rao A, Stuart J, Goldstein T, Salama S, Deyell R, Rassekh SR, Haussler D. Abstract PR14: Harnessing the power of big data to advance pediatric cancer care Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr14  0.664
2015 Youngren JF, Foye A, Thomas G, Stuart JM, Goldstein T, Robert B, Bivol A, Sokolov A, Ryan CJ, Pourmand N, Beer TM, Evans CP, Lara P, Gleave ME, Chi KN, et al. Abstract A12: Identification of pathways associated with abiraterone resistance in metastatic castration resistant prostate cancer: Preliminary results from the SU2C/AACR West Coast Prostate Cancer Dream Team Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-A12  0.52
2015 Baertsch R, Wong C, Youngren J, Stuart J, Small E, Goldstein T. Abstract A1-46: Using Medbook Workbench to create evidence streams to guide medical decisions Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-46  0.699
2015 Woodward J, King C, Coleman D, Lisac R, Schwartzman J, Wang N, Gleave M, Gray J, Thomas G, Beer TM, Hook KV, Baertsch R, Goldstein T, Stuart J, Gao L, et al. Abstract 731: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer Cancer Research. 75: 731-731. DOI: 10.1158/1538-7445.Am2015-731  0.703
2014 Thomas G, Youngren J, Ryan CJ, Beer TM, Gleave ME, Evans CP, Stuart J, Rettig M, Toschi A, Foye A, Alumkal JJ, Corless CL, Neff T, Baertsch R, Huang J, ... ... Goldstein TC, et al. Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Journal of Clinical Oncology. 32: 5088-5088. DOI: 10.1200/Jco.2014.32.15_Suppl.5088  0.694
2014 Bivol A, Baertsch R, Sokolov A, Paull E, Newton Y, Goldstein TC, Foye A, Pourmand N, Youngren J, Parulkar R, Lopez A, de Vere White R, Alumkal JJ, Toschi A, Beer TM, et al. Pathway-based signature analysis of RNA-seq data to reveal new targetable avenues for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Journal of Clinical Oncology. 32: 11078-11078. DOI: 10.1200/Jco.2014.32.15_Suppl.11078  0.682
2013 Goldstein TC, Paull EO, Ellis MJ, Stuart JM. Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3114-20. PMID 23430023 DOI: 10.1158/1078-0432.Ccr-12-2093  0.47
2013 Febbo PG, Goldstein TC, Baertsch R, Youngren J, Newton Y, Bivol A, Small EJ, Stuart JM. Identification of polo-like kinase 1 (PLK1) in aggressive prostate cancer by paradigm analysis. Journal of Clinical Oncology. 31: 5006-5006. DOI: 10.1200/Jco.2013.31.15_Suppl.5006  0.661
2013 Goldstein TC, Baertsch R, Febbo PG, Stuart J, Haussler D. Abstract 60: The MedBook network for cancer precision medical care. Cancer Research. 73: 60-60. DOI: 10.1158/1538-7445.Am2013-60  0.668
2013 Heiser LM, Shaw CA, Wang NJ, Grasso C, Anur P, Ng S, Goldstein T, Spellman PT, Stuart J, Osborne K, Gray J, Schiff R. Abstract 5238: Acquired therapeutic resistance is mediated by deregulation of multiple pathways. Cancer Research. 73: 5238-5238. DOI: 10.1158/1538-7445.Am2013-5238  0.419
2012 Ng S, Collisson EA, Sokolov A, Goldstein T, Gonzalez-Perez A, Lopez-Bigas N, Benz C, Haussler D, Stuart JM. PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis. Bioinformatics (Oxford, England). 28: i640-i646. PMID 22962493 DOI: 10.1093/Bioinformatics/Bts402  0.615
2012 Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 486: 353-60. PMID 22722193 DOI: 10.1038/Nature11143  0.438
2012 Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 2724-9. PMID 22003129 DOI: 10.1073/Pnas.1018854108  0.684
2012 Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Goiffon RJ, Wallis JW, Goldstein TC, Chen K, Allred DC, Leitch AM, Olson JA, Ota DM, Watson M, Piwnica-Worms D, et al. Whole genome sequencing to characterize luminal-type breast cancer. Journal of Clinical Oncology. 30: 503-503. DOI: 10.1200/Jco.2012.30.15_Suppl.503  0.415
2011 Listerman I, Gazzaniga FS, Heiser LM, Lukas JJ, Goldstein T, Haussler D, Gray JW, Blackburn EH. Abstract A58: Wnt signaling pathway components are associated with telomerase activity in breast cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-A58  0.594
Show low-probability matches.